Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | GSK3B | P49841 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | MITF | O75030 | 1/20 | 0.44 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29670000 | 1.00 | MEN1 (0.62) | MEN1KMT2ATSHRGSK3BMAPT | |
| SCHEMBL30016132 | 0.84 | GSK3B (0.59) | MEN1KMT2AGSK3BMAPTTP53 | |
| SCHEMBL1434608 | 0.84 | GSK3B (0.59) | MEN1KMT2AGSK3BMAPTTP53 | |
| SCHEMBL3233653 | 0.82 | CSNK2A1 (0.60) | MEN1KMT2ATSHRGSK3BMAPT | |
| SCHEMBL16523497 | 0.82 | GSK3B (0.48) | MEN1KMT2ATSHRGSK3BMAPT | |
| SCHEMBL31602938 | 0.82 | CSNK2A1 (0.60) | MEN1KMT2ATSHRGSK3BMAPT | |
| SCHEMBL31693367 | 0.82 | MEN1 (0.65) | MEN1KMT2ATSHRMAPTTP53 | |
| SCHEMBL9720686 | 0.82 | MEN1 (0.65) | MEN1KMT2ATSHRMAPTTP53 | |
| SCHEMBL29925088 | 0.81 | GSK3B (0.50) | MEN1KMT2ATSHRGSK3BMAPT | |
| SCHEMBL9901510 | 0.81 | RAB9A (0.50) | MEN1KMT2AGSK3BMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150364-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2024-05-09 | — | — | US | disclosed |
| US-20220389020-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2022-12-08 | — | — | US | disclosed |
| CN-109320458-B | Diaryl imidazole-containing compound, preparation method and medical application thereof | 中国药科大学 | 2022-05-31 | — | — | CN | disclosed |
| EP-3670514-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | Genentech, Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| US-10633377-B2 | Imidazole and thiazole compositions for modifying biological signaling | OHIO UNIVERSITY (US) | 2020-04-28 | — | — | US | disclosed |
| US-10407420-B2 | Imidazole and thiazole compositions for modifying biological signaling | OHIO UNIVERSITY (US) | 2019-09-10 | — | — | US | disclosed |
| US-10392381-B2 | Prevention and treatment of non-alcoholic fatty liver disease | OHIO UNIVERSITY (US) | 2019-08-27 | — | — | US | disclosed |
| US-10023567-B2 | Imidazole and thiazole compositions for modifying biological signaling | OHIO UNIVERSITY (US) | 2018-07-17 | — | — | US | disclosed |
| US-10023567-B2 | Imidazole and thiazole compositions for modifying biological signaling | OHIO UNIVERSITY (US) | 2018-07-17 | — | — | US | disclosed |
| EP-3333169-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | Genentech, Inc. (US) | 2018-06-13 | — | — | EP | disclosed |
| WO-2011003065-A2 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2011-01-06 | — | — | WO | disclosed |
| WO-2010051549-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2010-05-06 | — | — | WO | disclosed |
| US-6448265-B1 | CORTICOTROPIN RELEASING FACTOR(CRF); ANTIDEPRESSANT; (5-AMINO-1-(2,6-DICHLORO-4-TRIFLUOROMETHYLPHENYL)-3-METHYLSULFANYL-1H -PYRAZOL-4-YL)-(2,5-DIMETHYLPHENYL)METHANONE FOR EXAMPLE | PFIZER, INC. | 2002-09-10 | — | — | US | disclosed |
| US-6441018-B2 | TREATMENT OF A WIDE RANGE OF DISEASES INCLUDING STRESS-RELATED ILLNESSES. | PFIZER INC. | 2002-08-27 | — | — | US | disclosed |
| US-20020049227-A1 | PYRAZOLES AND PYRAZOLOPYRIMIDINES HAVING CRF ANTAGONISTIC ACTIVITY | FARACI WILLIAM STEPHAN (US) | 2002-04-25 | — | — | US | disclosed |
| US-20020016333-A1 | PYRAZOLES AND PYRAZOLOPYRIMIDINES HAVING CRF ANTAGONISTIC ACTIVITY | FARACI WILLIAM STEPHEN (US) | 2002-02-07 | — | — | US | disclosed |
| US-6103900-A | CORTICOTROPIN RELEASING FACTOR (CRF) ANTAGONIST WHICH TREAT STRESS-INDUCED DISEASES | PFIZER INC (US) | 2000-08-15 | — | — | US | disclosed |
| US-6005109-A | CORTICOTROPIN RELEASING FACTOR (CRF) ANTAGONIST ACTIVITY; EFFECTIVE IN THE TREATMENT OF A WIDE RANGE OF DISEASES INCLUDING STRESS-RELATED ILLNESSES | PFLIZER INC. (US) | 1999-12-21 | — | — | US | disclosed |
| EP-0674624-B1 | PYRAZOLES HAVING CRF ANTAGONIST ACTIVITY | PFIZER (US) | 1999-01-20 | — | — | EP | disclosed |
| US-5712303-A | ANTIDEPRESSANTS | PFIZER INC. (US) | 1998-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389020-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK1, JAK2, JAK3 | MEN1 2088/4885KMT2A 1561/4885TSHR 932/4885 |
| US-20020016333-A1 | PYRAZOLES AND PYRAZOLOPYRIMIDINES HAVING CRF ANTAGONISTIC ACTIVITY | CRH, CRHR1, CRHR2 | MEN1 2637/4885KMT2A 4103/4885TSHR 232/4885 |
| US-10392381-B2 | Prevention and treatment of non-alcoholic fatty liver disease | FABP1, LIPC, SLC10A1 | MEN1 4206/4885KMT2A 4190/4885TSHR 2168/4885 |
| US-10407420-B2 | Imidazole and thiazole compositions for modifying biological signaling | TYRO3, FGFR1, STAT6 | MEN1 1971/4885KMT2A 4627/4885TSHR 23/4885 |
| US-20240150364-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK1, JAK2, JAK3 | MEN1 2088/4885KMT2A 1561/4885TSHR 932/4885 |
| US-10633377-B2 | Imidazole and thiazole compositions for modifying biological signaling | TYRO3, FGFR1, STAT6 | MEN1 1988/4885KMT2A 4617/4885TSHR 23/4885 |
| US-20020049227-A1 | PYRAZOLES AND PYRAZOLOPYRIMIDINES HAVING CRF ANTAGONISTIC ACTIVITY | CRH, CRHR1, CRHR2 | MEN1 2637/4885KMT2A 4103/4885TSHR 232/4885 |
| US-10023567-B2 | Imidazole and thiazole compositions for modifying biological signaling | FGFR1, TYRO3, STAT6 | MEN1 1937/4885KMT2A 4554/4885TSHR 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.